Clinical Cases Podcast Series-FREE NO CME-Benzodiazepine Deprescribing Algorithm

Benzodiazepine Deprescribing Algorithm

Pdf Summary

The February 2019 Benzodiazepine & Z‑Drug (benzodiazepine receptor agonist; BZRA) Deprescribing Algorithm provides evidence-based guidance for when and how to taper and stop benzodiazepines and Z‑drugs used for insomnia. It aligns with NICE recommendations that these medicines be used only short term for insomnia and emphasizes shared decision-making.<br /><br />Deprescribing is recommended for: (1) adults aged 65+ taking a BZRA regardless of duration (due to higher risk and because BZRAs should not be first-line therapy in older people), and (2) adults aged 18–64 who have taken a BZRA for more than four weeks, particularly when insomnia is the only issue or when contributing comorbidities are already managed. Before tapering, clinicians should clarify why the BZRA was started (e.g., hospital-initiated for sleep, grief reaction, anxiety history) and assess for situations where continuation or specialist input may be needed, such as unmanaged anxiety/depression, other sleep disorders (e.g., restless legs), BZRA use specifically for anxiety, or alcohol withdrawal.<br /><br />The algorithm recommends a slow, patient-collaborative taper, commonly reducing the dose by about 25% every two weeks, with smaller reductions (e.g., 12.5%) near the end and/or planned drug-free days. Patients should be monitored every 1–2 weeks during tapering, with adjustments if symptoms recur (hold the dose for 1–2 weeks, then resume a slower taper). Switching to long-acting agents is not supported by evidence as superior for withdrawal; if dosage forms limit small reductions, strategies include initial larger reductions with drug-free days or switching to lorazepam/oxazepam for final steps.<br /><br />Non-drug insomnia management is central: behavioral sleep advice and cognitive behavioral therapy for insomnia (CBT-I), including stimulus control, sleep restriction, sleep hygiene, relaxation, and support. The rationale for deprescribing includes reduced long-term efficacy and risks such as dependence, falls, cognitive impairment, daytime sedation, and accidents, especially in older adults. Withdrawal symptoms (insomnia, anxiety, irritability, sweating, GI symptoms) are usually mild and transient.

Keywords

benzodiazepine deprescribing

BZRA tapering

insomnia management

shared decision-making

older adults

NICE guidelines

cognitive behavioral therapy for insomnia

withdrawal symptoms

dose reduction

sleep hygiene